IQVIA SOLUTIONS ASIA PTE. LTD.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Computer Processing and Data Preparation and Processing Services, Information Retrieval Services), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about IQVIA SOLUTIONS ASIA PTE. LTD.
Live alerts from global media, monitored by Business Radar
2025-03-20 (centerforbiosimilars.com)
Smart Tendering Policies Unlock Greater Biosimilar Savings
Tendering emerged as the most effective strategy for reducing costs and increasing biosimilar uptake in the retail setting, while price-linked discounts and prescribing quotas have shown mixed or uncertain results.
Read more
2025-02-20 (stocktitan.net)
IQVIA Sustainability Report Showcases Major ESG Milestones Across Global Operations | IQV Stock News
Global healthcare leader achieves 27% emissions reduction, expands clinical trial diversity, and launches responsible AI initiatives while earning top Fortune recognition.
Read more
2024-10-30 (centerforbiosimilars.com)
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Read more
2023-10-27 (europeanpharmaceuticalreview.com)
Sustainable biosimilar competition in Europe: can it be achieved?
Medicines for Europe has reflected on IQVIA's report that outlines factors for achieving sustainable levels of EU biosimilar competition.
Read more
(smartenergydecisions.com)
IQVIA Goals Validated by SBTi
IQVIA verified its GHG emissions reduction targets, including its net zero by 2050 target, with the Science Based Targets initiative (SBTi).
Read more